PMC3665239_01
Hemoglobin and creatine response with rituximab intervention.
CRIM.HEMATOLOGY2013-130978.001.jpg
PMC3665239_01_CRIM.HEMATOLOGY2013-130978.001.jpg
fig1
She remains in remission from the microangiopathic hemolytic anemia and thrombocytopenia now 11 months after her initial presentation, though her renal function has still not returned to her baseline (Figures 1 and 2, Table 1).
Platelet count, LDH, and haptoglobin response with rituximab intervention.
CRIM.HEMATOLOGY2013-130978.002.jpg
PMC3665239_01_CRIM.HEMATOLOGY2013-130978.002.jpg
fig2
She remains in remission from the microangiopathic hemolytic anemia and thrombocytopenia now 11 months after her initial presentation, though her renal function has still not returned to her baseline (Figures 1 and 2, Table 1).